# Study of TTX-MC138 in Subjects With Advanced Solid Tumors

> **NCT06260774** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **TransCode Therapeutics** · enrollment: 16 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** TTX-MC138

## Key facts

- **NCT ID:** NCT06260774
- **Lead sponsor:** TransCode Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-05
- **Primary completion:** 2025-09-30
- **Final completion:** 2027-02-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06260774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06260774, "Study of TTX-MC138 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06260774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*